Last reviewed · How we verify
LIQ861 Inhaled Treprostinil
LIQ861 Inhaled Treprostinil is a Prostacyclin analog Small molecule drug developed by Liquidia Technologies, Inc.. It is currently in Phase 3 development for Pulmonary arterial hypertension (PAH). Also known as: Inhaled treprostinil, Inhaled prostacyclin, inhaled treprostinil, inhaled prostacyclin.
LIQ861 is an inhaled formulation of treprostinil, a prostacyclin analog that vasodilates pulmonary and systemic blood vessels by activating prostacyclin receptors.
LIQ861 is an inhaled formulation of treprostinil, a prostacyclin analog that vasodilates pulmonary and systemic blood vessels by activating prostacyclin receptors. Used for Pulmonary arterial hypertension (PAH).
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | LIQ861 Inhaled Treprostinil |
|---|---|
| Also known as | Inhaled treprostinil, Inhaled prostacyclin, inhaled treprostinil, inhaled prostacyclin |
| Sponsor | Liquidia Technologies, Inc. |
| Drug class | Prostacyclin analog |
| Target | Prostacyclin receptor (IP receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Pulmonary Hypertension |
| Phase | Phase 3 |
Mechanism of action
Treprostinil mimics the action of prostacyclin, a naturally occurring eicosanoid that promotes vasodilation and inhibits platelet aggregation. By binding to prostacyclin receptors on vascular smooth muscle cells, it reduces pulmonary vascular resistance and improves blood flow. The inhaled delivery via Liquidia's proprietary LIQ technology allows direct lung deposition with potentially improved tolerability compared to systemic routes.
Approved indications
- Pulmonary arterial hypertension (PAH)
Common side effects
- Cough
- Headache
- Throat irritation
- Flushing
- Jaw pain
Key clinical trials
- An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
- Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil (PHASE3)
- Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil (PHASE3)
- Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LIQ861 Inhaled Treprostinil CI brief — competitive landscape report
- LIQ861 Inhaled Treprostinil updates RSS · CI watch RSS
- Liquidia Technologies, Inc. portfolio CI
Frequently asked questions about LIQ861 Inhaled Treprostinil
What is LIQ861 Inhaled Treprostinil?
How does LIQ861 Inhaled Treprostinil work?
What is LIQ861 Inhaled Treprostinil used for?
Who makes LIQ861 Inhaled Treprostinil?
Is LIQ861 Inhaled Treprostinil also known as anything else?
What drug class is LIQ861 Inhaled Treprostinil in?
What development phase is LIQ861 Inhaled Treprostinil in?
What are the side effects of LIQ861 Inhaled Treprostinil?
What does LIQ861 Inhaled Treprostinil target?
Related
- Drug class: All Prostacyclin analog drugs
- Target: All drugs targeting Prostacyclin receptor (IP receptor)
- Manufacturer: Liquidia Technologies, Inc. — full pipeline
- Therapeutic area: All drugs in Cardiovascular / Pulmonary Hypertension
- Indication: Drugs for Pulmonary arterial hypertension (PAH)
- Also known as: Inhaled treprostinil, Inhaled prostacyclin, inhaled treprostinil, inhaled prostacyclin